At the 2023 ASCO meeting, RudaCure registered an abstract for RCI002, its chemotherapy-induced pain treatment compound, and presented the preclinical results of the drug to many international researchers.
In particular, this attendance was as part of the KONECT clinical trial delegation, which provided a venue to discuss clinical topics related to ADC and CAR-T in the oncology field, along with related diseases and side effects, as well as an opportunity to introduce the efficacy of RCI002 in pain treatment.
RudaCure Clinical Director Yuseung Ha explaining RCI002 to a WRNMC Oncology Pharmacist
RCI002 Development Project Owner Manager Minjung Kim, Abbvie RA representative, WRNMC Pharmacist, Clinical Director Yuseung Ha
데일리팜: 데일리팜